Table 2 Clinical and laboratory adverse events of antifungal prophylaxis
Variable | L-AmB (n = 60) | CAS (n = 60) | Difference (95% CI) | |
|---|---|---|---|---|
No. of patients (%) | Percentage points | p-Value | ||
Drug-related adverse events | ||||
Clinical (Total) | 5 (8.33) | 2 (3.33) | 5.0 (−3.4 to 13.4) | 0.243 |
Fever | 1 (1.67) | 1 (1.67) | 0.0 (−4.6 to 4.6) | 1.0 |
Nausea | 1 (1.67) | 0 | 1.7 (−1.6 to 4.9) | 0.315 |
Headache | 2 (3.33) | 1 (1.67) | 1.7 (−3.9 to 7.3) | 0.559 |
Bone pain | 1 (1.67) | 0 | 1.7 (−1.6 to 4.9) | 0.315 |
Increase in alanine aminotransferase | ||||
≥ 1.5 × normal value 39 U/L | 13 (21.67) | 14 (23.33) | −1.7 (−16.6 to 13.3) | 0.827 |
≥ 2.5 × normal value 39 U/L | 3 (5.0) | 8 (13.33) | −8.3 (−18.7 to 2.0) | 0.144 |
Increase in aspartate aminotransferase | ||||
≥ 1.5 × normal value 39 U/L | 15 (25.0) | 19 (31.67) | −6.7 (−22.7 to 9.4) | 0.416 |
≥ 2.5 × normal value 39 U/L | 6 (10.0) | 2 (3.33) | 6.7 (−2.2 to 15.5) | 0.140 |
Increase in alkaline phosphatase | ||||
≥ 1.5 × normal value 320 U/L | 0 | 0 | 0 | 1.0 |
≥ 2.5 × normal value 320 U/L | 0 | 0 | 0 | 1.0 |
Increase in total bilirubin | ||||
≥ 1.5 × normal value 1.1 mg/dl | 3 (5.0) | 0 | 5.0 (−0.6 to 10.6) | 0.079 |
≥ 2.5 × normal value 1.1 mg/dl | 0 | 0 | 0 | 1.0 |
Increase in direct bilirubin | ||||
≥ 1.5 × normal value 0.3 mg/dl | 9 (15.0) | 5 (8.33) | 6.7 (−4.8 to 18.2) | 0.255 |
≥ 2.5 × normal value 0.3 mg/dl | 3 (5.0) | 2 (3.33) | 1.7 (−5.5 to 8.8) | 0.648 |
Increase in creatinine | ||||
≥ 1.5 × normal value 0.7 mg/dl | 0 | 0 | 0 | 1.0 |
≥ 2.5 × normal value 0.7 mg/dl | 0 | 0 | 0 | 1.0 |
Increase in urea | ||||
≥ 1.5 × normal value 46 mg/dl | 3 (5.0) | 2 (3.33) | 1.7 (−5.5 to 8.8) | 0.648 |
≥ 2.5 × normal value 46 mg/dl | 0 | 0 | 0 | 1.0 |
Decrease potassium | ||||
≤ 3.4 mmol/L | 46 (76.67) | 34 (56.67) | −20.0 (−3.1 to −36.9) | 0.02 |
≤ 2.4 mmol/L | 2 (3.33) | 0 | −3.3 (1.2 to −7.9) | 0.154 |